National Research Corporation Announces First Quarter 2016 Results
/EINPresswire.com/ -- LINCOLN, NE--(Marketwired - May 03, 2016) - National Research Corporation (NASDAQ: NRCIA)(NASDAQ: NRCIB) today announced results for the first quarter of 2016.
- Net New Sales $5.9 million, up 18%
- Total Contract Value $111.3 million
- Revenue up 6% to $27.9 million
- Net Income of $5.2 million, up 49%
Remarking on Company performance, Michael D. Hays, chief executive officer of National Research Corporation said, "Double-digit growth in sales and net income shows strong financial performance which, combined with progress against our strategic initiatives, resulted in a very rewarding quarter."
Revenue for the quarter ended March 31, 2016, was $27.9 million, compared to $26.3 million for the same quarter in 2015. Net income for the quarter ended March 31, 2016, was $5.2 million, compared to $3.5 million for the quarter ended March 31, 2015. Diluted earnings per share increased to $0.12 for Class A shares and $0.73 for Class B shares for the quarter ended March 31 2016, from diluted earnings per share of $0.08 for Class A shares and $0.49 for Class B shares for the quarter ended March 31, 2015. Combined diluted earnings per share (a non-GAAP measure) increased to $0.21 for the quarter ended March 31, 2016, from $0.14 for the first quarter of 2015.
Regarding first quarter performance, Kevin Karas, chief financial officer of National Research Corporation, said, "Continued strong net new sales growth and increased client retention in the first quarter combined to drive significant improvement in our organic revenue growth rate. Revenue grew at a 6% rate in the first quarter, which is an 8% growth rate adjusted for the sale of our clinical workflow tool."
A listen-only simulcast of National Research Corporation's 2016 first quarter conference call will be available online at http://edge.media-server.com/m/p/gm9jwhzj on May 4, 2016, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.
For more than 35 years, National Research Corporation has been at the forefront of patient-centered care, helping healthcare providers measure and improve quality and services through analytics that offer a rich understanding of customers' experiences, preferences, risks and behaviors across the healthcare continuum.
The information discussed within this release includes financial results and projections that are in accordance with accounting principles generally accepted in the United States (GAAP). In addition, certain non-GAAP financial measures have been provided that calculate combined earnings per share based on combined Class A and Class B shares and share equivalents outstanding, respectively. The non-GAAP measures should be read in conjunction with the corresponding GAAP measures and should be considered in addition to, and not as an alternative or substitute for, the measures prepared in accordance with GAAP. Please note that the Company's non-GAAP measures may be different than those used by other companies. The additional non-GAAP financial information the Company presents should be considered in conjunction with, and not as a substitute for, the Company's financial information presented in accordance with GAAP. The non-GAAP financial measures are provided in an effort to provide information that investors may deem relevant to evaluate results from the company's core business operations and to compare the company's performance with prior periods. The company uses both GAAP and these non-GAAP financial measures for evaluating comparable financial performance against prior periods.
This press release includes "forward-looking" statements related to the Company that can generally be identified as describing the Company's future plans, objectives or goals. Such forward-looking statements are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those currently anticipated. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For further information about the factors that could affect the Company's future results, please see the Company's filings with the Securities and Exchange Commission.
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Statements of Income
(In thousands, except per share data)
Three months ended
March 31,
--------------------
2016 2015
--------- ---------
Revenue $ 27,870 $ 26,270
Operating expenses:
Direct 11,539 11,799
Selling, general and administrative 7,357 7,627
Depreciation and amortization 968 1,015
--------- ---------
Total operating expenses 19,864 20,441
--------- ---------
Operating income 8,006 5,829
Other income (expense):
Interest income 11 17
Interest expense (85) (63)
Other, net 74 (1)
--------- ---------
Total other expense -- (47)
--------- ---------
Income before income taxes 8,006 5,782
Provision for income taxes 2,833 2,302
--------- ---------
Net income $ 5,173 $ 3,480
========= =========
Earnings Per Share of Common Stock:
Basic Earnings Per Share:
Class A $ 0.12 $ 0.08
========= =========
Class B $ 0.74 $ 0.50
========= =========
Diluted Earnings Per Share:
Class A $ 0.12 $ 0.08
========= =========
Class B $ 0.73 $ 0.49
========= =========
Weighted average shares and share equivalents
outstanding
Class A - Basic 20,710 20,792
========= =========
Class B - Basic 3,489 3,478
========= =========
Class A - Diluted 20,948 21,033
========= =========
Class B - Diluted 3,531 3,524
========= =========
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Balance Sheets
(Dollars in thousands, except per share amounts and par value)
Mar. 31, Dec. 31,
2016 2015
--------- ---------
ASSETS
Current Assets:
Cash and cash equivalents $ 25,366 $ 42,145
Accounts receivable, net 14,101 9,808
Income taxes receivable 1,919 157
Other current assets 3,428 2,951
--------- ---------
Total Current Assets 44,814 55,061
Property and equipment, net 11,631 11,125
Goodwill 57,944 57,792
Other, net 3,981 4,071
--------- ---------
Total Assets $ 118,370 $ 128,049
========= =========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable and accrued expenses $ 4,354 $ 3,394
Deferred revenue 17,877 14,843
Accrued compensation 4,496 4,391
Dividends payable 3,369 18,440
Income taxes payable - 701
Notes payable 2,422 2,402
--------- ---------
Total Current Liabilities 32,518 44,171
--------- ---------
Non-Current Liabilities 9,682 9,656
--------- ---------
Total Liabilities 42,200 53,827
Shareholders' Equity:
Preferred stock, $0.01 par value, authorized
2,000,000 shares, none issued -- --
Class A Common stock, $0.001 par value; authorized
60,000,000 shares, issued 25,646,624 in 2016 and
25,592,812 in 2015, outstanding 20,894,893 in 2016
and 20,848,168 in 2015 26 26
Class B Common stock, $0.001 par value; authorized
80,000,000 shares, issued 4,298,886 in 2016 and
4,271,413 in 2015, outstanding 3,536,496 in 2016
and 3,510,150 in 2015 4 4
Additional paid-in capital 43,519 44,103
Retained earnings 67,118 65,313
Accumulated other comprehensive loss (2,121) (2,995)
Treasury stock (32,376) (32,229)
--------- ---------
Total Shareholders' Equity 76,170 74,222
--------- ---------
Total Liabilities and Shareholders' Equity $ 118,370 $ 128,049
========= =========
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Non-GAAP Combined Earnings Per Share Schedule
(In thousands, except per share data)
Three months ended
March 31,
---------------------
2016 2015
---------- ----------
Combined Earnings Per Share
Basic Earnings Per Share $ 0.21 $ 0.14
========== ==========
Diluted Earnings Per Share $ 0.21 $ 0.14
========== ==========
Combined weighted average shares and share equivalents
outstanding
Combined - Basic 24,270
24,198
========== ==========
Combined - Diluted 24,479 24,557
========== ==========
Contact:
Kevin R. Karas
Chief Financial Officer
402-475-2525
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
